Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits.
Cancer cell
| Authors | |
| Abstract | Zhang et al. report a randomized phase 2 trial for diffuse large B cell lymphoma (DLBCL) that compared standard of care (R-CHOP) to R-CHOP combined with one of 5 agents matched to an individual lymphoma's genetics. Overall, the matching strategy significantly outperformed R-CHOP, laying the foundation for a paradigm-shifting phase 3 trial. |
| Year of Publication | 2023
|
| Journal | Cancer cell
|
| Date Published | 09/2023
|
| ISSN | 1878-3686
|
| DOI | 10.1016/j.ccell.2023.08.005
|
| PubMed ID | 37774696
|
| Links |